0JGL Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.82 |
| 52 Week High | NOK 5.31 |
| 52 Week Low | NOK 2.02 |
| Beta | 1.89 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -36.34% |
| 33 Year Change | n/a |
| 5 Year Change | -94.82% |
| Change since IPO | -92.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JGL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.8% |
| 1Y | -36.3% | -16.8% | 9.2% |
Return vs Industry: 0JGL underperformed the UK Biotechs industry which returned -26.4% over the past year.
Return vs Market: 0JGL underperformed the UK Market which returned -2.5% over the past year.
Price Volatility
| 0JGL volatility | |
|---|---|
| 0JGL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JGL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0JGL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 14 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.
PCI Biotech Holding ASA Fundamentals Summary
| 0JGL fundamental statistics | |
|---|---|
| Market cap | NOK 74.58m |
| Earnings (TTM) | -NOK 55.09m |
| Revenue (TTM) | NOK 4.75m |
15.7x
P/S Ratio-1.4x
P/E RatioIs 0JGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JGL income statement (TTM) | |
|---|---|
| Revenue | NOK 4.75m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 4.75m |
| Other Expenses | NOK 59.85m |
| Earnings | -NOK 55.09m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 12, 2023
| Earnings per share (EPS) | -1.48 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,159.89% |
| Debt/Equity Ratio | 0% |
How did 0JGL perform over the long term?
See historical performance and comparison